Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

NCT07674771 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Castration Sensitive Prostate Cancer
Metastatic Prostate Cancer
Adaptive Radiotherapy

Interventions

DRUG: Drug: 68-Ga PSMA11
RADIATION: Adaptive stereotactic ablative radiotherapy (SABR)
DRUG: 68Ga-PSMA-11
RADIATION: Adaptive stereotactive ablative radiotherapy (SABR)

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]
[object Object]